177Lu-PSMA raDioligand therapy for prostate cancer

Abstract

177Lu-prostate-specific membrane antigen (PSMA) raDioligand therapy (RLT) using inhibitors of PSMA is a novel therapeutic option in patients withmetastatic castration-resistant prostate cancer. The current literature suggests that this therapy is well tolerated and effective. On the basis of clinical need and current evidence, the therapy is being implemented in a growing number of centers worldwide. Here, we review important aspects of 177Lu-PSMA RLT, incluDing patient stratification, the therapy protocol, concomitant meDication, and follow-up, to inform meDical staff involved in the RLT and care of patients with metastatic castration-resistant prostate cancer.